CA2431919A1 - Ccr5 antagonist and dp-178 polypeptide for treating viral infections - Google Patents

Ccr5 antagonist and dp-178 polypeptide for treating viral infections Download PDF

Info

Publication number
CA2431919A1
CA2431919A1 CA002431919A CA2431919A CA2431919A1 CA 2431919 A1 CA2431919 A1 CA 2431919A1 CA 002431919 A CA002431919 A CA 002431919A CA 2431919 A CA2431919 A CA 2431919A CA 2431919 A1 CA2431919 A1 CA 2431919A1
Authority
CA
Canada
Prior art keywords
polypeptide
pharmaceutically acceptable
hiv
ccr5 antagonist
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002431919A
Other languages
English (en)
French (fr)
Inventor
Bahige M. Baroudy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2431919A1 publication Critical patent/CA2431919A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
CA002431919A 2000-12-19 2001-12-17 Ccr5 antagonist and dp-178 polypeptide for treating viral infections Abandoned CA2431919A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25665700P 2000-12-19 2000-12-19
US60/256,657 2000-12-19
PCT/US2001/048802 WO2002056902A2 (en) 2000-12-19 2001-12-17 Ccr5 antagonist and dp-178 polypeptide for treating viral infections

Publications (1)

Publication Number Publication Date
CA2431919A1 true CA2431919A1 (en) 2002-07-25

Family

ID=22973061

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002431919A Abandoned CA2431919A1 (en) 2000-12-19 2001-12-17 Ccr5 antagonist and dp-178 polypeptide for treating viral infections

Country Status (12)

Country Link
US (1) US20050065319A1 (enExample)
EP (1) EP1385534A2 (enExample)
JP (1) JP2005500981A (enExample)
CN (1) CN1481251A (enExample)
AR (1) AR031931A1 (enExample)
BR (1) BR0116253A (enExample)
CA (1) CA2431919A1 (enExample)
HU (1) HUP0302241A3 (enExample)
MX (1) MXPA03005526A (enExample)
NO (1) NO20032769L (enExample)
WO (1) WO2002056902A2 (enExample)
ZA (1) ZA200304560B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2400553A (en) * 2003-04-14 2004-10-20 Cipla Ltd Antiviral pharmaceutical combination of lamivudine, stavudine and efavirenz, or derivatives thereof
BRPI0410360A (pt) * 2003-05-16 2006-08-01 Univ Maryland Biotech Inst composições para a sub-regulação da expressão de ccr5 e métodos para seu uso
CA2587903A1 (en) 2004-11-17 2006-05-26 Amgen Fremont Inc. Fully human monoclonal antibodies to il-13
JP2009517474A (ja) * 2005-11-30 2009-04-30 シェーリング コーポレイション Ｃｃｒ５拮抗剤およびｃｘｃｒ４拮抗剤の組み合わせを含む組成物
EP1976497A2 (en) * 2005-12-01 2008-10-08 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Treatment of viral infections
EP1886696A1 (en) * 2006-08-03 2008-02-13 Endotis Pharma Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins
WO2013127299A1 (zh) * 2012-02-28 2013-09-06 中国人民解放军军事医学科学院毒物药物研究所 用于抑制hiv的多肽及其作用靶点
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
CA2224008C (en) * 1995-06-07 2009-08-18 Trimeris, Inc. The treatment of hiv and other viral infections using combinatorial therapy
US6281331B1 (en) * 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
CA2365900A1 (en) * 1999-05-04 2000-11-09 Schering Corporation Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
US6689765B2 (en) * 1999-05-04 2004-02-10 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
PT1175402E (pt) * 1999-05-04 2005-11-30 Schering Corp Derivados da piperidina uteis como antagonistas ccr5
US6387930B1 (en) * 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists

Also Published As

Publication number Publication date
NO20032769L (no) 2003-08-18
HUP0302241A2 (hu) 2003-11-28
US20050065319A1 (en) 2005-03-24
WO2002056902A3 (en) 2002-12-05
WO2002056902A2 (en) 2002-07-25
ZA200304560B (en) 2005-07-27
BR0116253A (pt) 2006-05-02
MXPA03005526A (es) 2003-10-06
EP1385534A2 (en) 2004-02-04
CN1481251A (zh) 2004-03-10
JP2005500981A (ja) 2005-01-13
HUP0302241A3 (en) 2005-06-28
NO20032769D0 (no) 2003-06-18
AR031931A1 (es) 2003-10-08

Similar Documents

Publication Publication Date Title
AU776541B2 (en) Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
US6861059B2 (en) Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations
AU2002255947B2 (en) CCR5 antagonists useful for treating aids
CA2431919A1 (en) Ccr5 antagonist and dp-178 polypeptide for treating viral infections
US6635646B1 (en) Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
US20070123538A1 (en) Compositions comprising a combination of CCR5 and CXCR4 antagonists
MXPA02008756A (es) Terapia adyuvante inmune de virus de inmunodeficiencia humana.
Aristoff Dihydropyrone sulfonamides as a promising new class of HIV protease inhibitors
TW200427682A (en) Piperidine derivatives useful as ccr5 antagonists
AU2002245148A1 (en) CCR5 antagonist and DP-178 polypeptide for treating viral infections
JP2005500981A5 (enExample)
US20070203149A1 (en) Ccr5 antagonists useful for treating hiv
MX2008007042A (en) Compositions comprising a combination of ccr5 and cxcr4 antagonists

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued